Skip to main content
NCBI home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1985 Jun;39(2):117–122. doi: 10.1136/jech.39.2.117

Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin.

J D Kark, S Bar-Shany, S Shor, L Merlinski, E Nili
PMCID: PMC1052418  PMID: 3891900

Abstract

Seroconversion to hepatitis A virus was studied in a sub sample of 802 Israeli military recruits (611 men and 191 women) who were taking part in a randomised controlled trial of pre-exposure immune serum globulin (ISG) for the prevention of viral hepatitis. On intake into the service 35% of the men and 47% of the women were negative to hepatitis. A virus antibody (anti-HAV). After three years 7 of 71 men (9.9%) who had not received pre-exposure ISG had become positive to anti-HAV compared to 2 of 83 (2.4%) who had received it; the statistical significance of this difference was p = 0.052. At two years 2 of 30 women (6.7%) who had not received ISG had converted compared to 1 of 43 (2.3%) who had received ISG (p = 0.37). Pooling the sexes gave conversion rates of 8.9% in those not immunised and 2.4% in those immunised (p = 0.029). The sex adjusted odds ratio was 4.0 (95% confidence limits 1.3-19.0). The morbidity rates for clinical non B hepatitis over the three year period among 12 835 men were 7.2 per 1000 in those not immunised and 3.6 per 1000 in those immunised (p = 0.004). Point estimates of the ratio of clinical hepatitis to seroconversion in men ranged from 0.25 to 0.30. It is concluded that pre-exposure administration of ISG effectively prevented clinical expression of viral hepatitis, apparently reduced seroconversion, and did not induce passive-active immunisation.

Full text

PDF
117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bar-Shany S., Nagan L., Szmuness W. [Prevalence of antibodies to hepatitis: anti-HA and anti-HBs]. Harefuah. 1977 Dec 15;93(12):390–392. [PubMed] [Google Scholar]
  2. Coulepis A. G., Locarnini S. A., Lehmann N. I., Gust I. D. Detection of hepatitis A virus in the feces of patients with naturally acquired infections. J Infect Dis. 1980 Feb;141(2):151–156. doi: 10.1093/infdis/141.2.151. [DOI] [PubMed] [Google Scholar]
  3. Frösner G. G., Overby L. R., Flehmig B., Gerth H. J., Haas H., Decker R. H., Ling C. M., Zuckerman A. J., Frösner H. R. Seroepidemiological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol. 1977;1(3):163–173. doi: 10.1002/jmv.1890010303. [DOI] [PubMed] [Google Scholar]
  4. Kark J. D., Bar-Shani S. Hepatitis A antibody in Israel Defence Forces recruits. J Med Virol. 1981;6(4):341–345. doi: 10.1002/jmv.1890060409. [DOI] [PubMed] [Google Scholar]
  5. Kark J. D. Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis in army recruits. J Epidemiol Community Health. 1982 Sep;36(3):176–182. doi: 10.1136/jech.36.3.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kark J. D., Witztum E., Mazkin H., Nili E., Danon Y. L. The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis. Infection. 1984 Jul-Aug;12(4):251–255. doi: 10.1007/BF01645952. [DOI] [PubMed] [Google Scholar]
  7. Rakela J., Nugent E., Mosley J. W. Viral hepatitis: enzyme assays and serologic procedures in the study of an epidemic. Am J Epidemiol. 1977 Dec;106(6):493–501. doi: 10.1093/oxfordjournals.aje.a112497. [DOI] [PubMed] [Google Scholar]
  8. Routenberg J. A., Dienstag J. L., Harrison W. O., Kilpatrick M. E., Hooper R. R., Chisari F. V., Purcell R. H., Fornes M. F. Foodborne outbreak of hepatitis A: clinical and laboratory features of acute and protracted illness. Am J Med Sci. 1979 Sep-Oct;278(2):123–137. [PubMed] [Google Scholar]
  9. Villarejos V. M., Serra J., Anderson-Visona K., Mosley J. W. Hepatitis A virus infection in households. Am J Epidemiol. 1982 Apr;115(4):577–586. doi: 10.1093/oxfordjournals.aje.a113339. [DOI] [PubMed] [Google Scholar]
  10. Weiland O., Berg J. V., Bäck E., Lundbergh P. Immunoglobulin prophylaxis against hepatitis A among Swedish UN soldiers in an endemic region. Infection. 1979;7(5):223–225. doi: 10.1007/BF01648930. [DOI] [PubMed] [Google Scholar]
  11. Weiland O. Hepatitis A. Aspects on prophylaxis and a comparison with hepatitis B and hepatitis non-A, non-B on epidemiology and prognosis. Scand J Infect Dis Suppl. 1981;28:1–73. doi: 10.3109/inf.1981.13.suppl-28.01. [DOI] [PubMed] [Google Scholar]
  12. Weiland O., Niklasson B., Berg R., Lundbergh P., Tideström L. Clinical and subclinical hepatitis A occurring after immunoglobulin prophylaxis among Swedish UN soldiers in Sinai. Scand J Gastroenterol. 1981;16(8):967–972. doi: 10.3109/00365528109181012. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES